

# SCIENTIFIC REPORTS



OPEN

## Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis


Emil ter Veer<sup>1</sup>, Lok Lam Ngai<sup>1</sup>, Gert van Valkenhoef<sup>2</sup>, Nadia Haj Mohammad<sup>1</sup>, Maarten C. J. Andereg<sup>3</sup>, Martijn G. H. van Oijen<sup>1</sup> & Hanneke W. M. van Laarhoven<sup>1</sup>

As evidence is inconsistent and based on either isolated Asian or Western studies, we conducted a network meta-analysis (NMA) to examine efficacy and safety of 5-FU (5-fluorouracil), capecitabine and S-1-based first-line treatment of advanced esophagogastric cancer in Asian and Western patients. Medline, EMBASE, CENTRAL and conferences ASCO and ESMO were searched up to January 2016 for randomized-controlled-trials comparing 5-FU, capecitabine or S-1-based regimens with equal chemotherapy backbones. Direct and indirect data for overall survival (OS) and progression-free-survival (PFS) were combined on the Hazard Ratio (HR)-scale using random-effects NMA and calculated as combined HRs and 95%credible intervals (95%CrI). Grade 1-2 and grade 3-4 adverse events were compared with pair-wise meta-analysis. Fifteen studies were identified including capecitabine (n = 945), 5-FU (n = 2,132) or S-1 (n = 1,636). No differences were found in respectively OS and PFS for capecitabine-based versus 5-FU-based regimens (HR = 0.89, 95%CrI = 0.76–1.04 and HR = 0.98, 95%CrI = 0.75–1.32), S-1-based versus 5-FU-based regimens (HR = 0.92, 95%CrI = 0.82–1.04 and HR = 0.88, 95%CrI = 0.70–1.11) and S-1-based versus capecitabine-based regimens (HR = 1.03, 95%CrI = 0.87–1.22 and HR = 0.89, 95%CrI = 0.65–1.20). Effects were similar in Asian and Western subgroups. Toxicity profiles were different but a lower frequency of relevant adverse events was observed with S-1. In conclusion, as efficacy was similar, choosing fluoropyrimidines should be based on their individual toxicity profiles.

Advanced esophagogastric adenocarcinoma (AEGC) of the stomach, gastro-esophageal junction (GEJ) or esophagus is one of the major causes of cancer-specific mortality<sup>1</sup>. In the late nineties, it was shown that survival could be extended by palliative chemotherapy<sup>2</sup>. After two decades of clinical studies, fluoropyrimidines are still the cornerstone of first-line treatment for advanced esophagogastric cancer. In addition to 5-fluorouracil (5-FU), also two novel fluoropyrimidine compounds have been introduced in first-line treatment of AEGC: capecitabine and S-1. Capecitabine is more frequently prescribed in Western countries, whereas S-1 is more frequently prescribed in Asian countries. Usually, a fluoropyrimidine is combined with either a platinum agent, a taxane or irinotecan<sup>3,4</sup>.

Whether 5-FU, capecitabine and S-1 based chemotherapy regimens are equally effective in first-line treatment of AEGC is still under debate<sup>5</sup>. There is evidence that there is no difference in efficacy between the three fluoropyrimidines and that S-1 has a more favourable toxicity profile from a previously conducted pair-wise meta-analysis<sup>6</sup>. However, Asian patients may respond differently to S-1 than Western patients, which might be explained by variations in metabolism<sup>7</sup>. The two novel oral fluoropyrimidines capecitabine and S-1 were

<sup>1</sup>Cancer Centre Amsterdam, Department of Medical Oncology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. <sup>2</sup>Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. <sup>3</sup>Department of Surgery, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. Correspondence and requests for materials should be addressed to H.W.M.v.L. (email: [h.vanlaarhoven@amc.uva.nl](mailto:h.vanlaarhoven@amc.uva.nl))



**Figure 1.** Flowchart of included studies. Flowchart of references derived from database search (left) and from conference search (right).

compared in only a three small phase II RCTs in an Asian patient population, which makes it difficult to explore the specific benefits of capecitabine-based or S-1 based regimens on a global scale<sup>8–10</sup>.

Furthermore, the differences in efficacy and toxicity between capecitabine-based and 5-FU-based regimens have not been addressed previously with meta-analysis including the newest studies. After completion of the REAL-2 study, which found that capecitabine and 5-FU-based regimens were equally effective<sup>11</sup>, a pooled analysis of the REAL-2 trial and the ML17032 trial<sup>12</sup> indicated a small benefit in survival of capecitabine-based over 5-FU based regimens<sup>13</sup>. Since then, another RCT on this topic has been conducted with conflicting results<sup>14</sup>. Given the available evidence, differences in efficacy between capecitabine-based and 5-FU-based regimens are difficult to explore by pair-wise analyses alone, and network-meta-analyses (NMA) may be more appropriate.

In NMA, a common comparator is used to estimate indirect relative effects between treatments<sup>15</sup>. Both direct and indirect relative treatment estimations can be combined into a combined effect-size. The benefit of this approach is that the precision of the effect estimate is increased and cross-validated among all available studies<sup>16</sup>. Moreover, in case of a low number of direct head-to-head RCTs, NMA can increase power to detect statistically significant differences. Therefore, we conducted a systematic review with NMA to examine the relative efficacy and safety of 5-FU, capecitabine and S-1 based regimens in first-line treatment of AEGC.


## Results

**Description of the included studies.** A total of 5,145 unique titles were retrieved through the database search, of which 22 RCTs remained after screening the titles and abstracts. After full-text assessment, 12 were excluded and ten were found eligible. In addition, five studies retrieved from the conference search were found eligible (Fig. 1). In total, 15 studies containing 4,713 patients were eligible<sup>8–12, 14, 17–25</sup>. The number of patients that received capecitabine-based, 5-FU-based and S-1 based regimens was 945, 2,132 and 1,636 respectively (Fig. 2 and Table 1). HRs for OS and PFS could be extracted in 14 and 9 studies respectively.

No major differences in study characteristics were observed (Table 1). The number of Western and Asian studies was five ( $n = 2652$  patients, 56.3%) and ten ( $n = 2061$  patients, 43.7%), respectively (Table 1). Seven (46.7%) studies were rated as low risk of bias for the primary outcome OS (Supplementary Figure 1A). Two (13.3%) and three (20.0%) studies were rated as unclear risk of bias on only one item or two items, respectively. The other three studies (20.0%) were rated as unclear on three items or were reported as abstract only. The risk of bias assessment for PFS is summarized in Supplementary Figure 1B.

**Efficacy.** For OS, no significant differences were found by NMA for capecitabine-based ( $n = 798$ ) compared to 5-FU-based regimens ( $n = 780$ ), combined HR 0.89 (95%CrI 0.76–1.04), for S-1 based ( $n = 1353$ ) compared to 5-FU-based regimens ( $n = 1224$ ), combined HR 0.92 (95%CrI 0.82–1.04), and for S-1 based ( $n = 164$ ) compared to capecitabine-based regimens ( $n = 165$ ), combined HR 1.03 (95%CrI 0.87–1.22) (Fig. 3A). The results of the current NMA for S-1 based versus 5-FU-based and S-1-based versus capecitabine-based were in line with the results of the pair-wise meta-analysis (reported previously)<sup>6</sup>.

For the secondary outcome PFS, no significant differences were found by NMA for capecitabine-based ( $n = 753$ ) compared to 5-FU-based regimens ( $n = 740$ ), combined HR 0.98 (95%CrI 0.75–1.32), for S-1 based



**Figure 2.** The network meta-analysis. Studies that contained 5-FU, capecitabine or S-1 based regimens with an equal backbone were analysed in a 3-node network. The size of each node corresponds to the number of patients that were randomized to receive S-1 ( $n = 1636$ ), capecitabine ( $n = 945$ ) and 5-FU based therapy ( $n = 2132$ ). The lines connect the regimens that were directly compared in head-to-head RCTs. The thickness of the lines corresponds to the number of RCTs. Abbreviations: 5-FU: 5-fluorouracil.

( $n = 1201$ ) compared to 5-FU-based regimens ( $n = 1063$ ), combined HR 0.88 (95%CrI 0.70–1.11) and for S-1 based ( $n = 99$ ) compared to capecitabine-based regimens ( $n = 101$ ), combined HR 0.89 (0.95%CrI 0.65–1.20) (Fig. 3B). A statistically significant portion of heterogeneity was found for S-1 based compared to 5-FU-based regimens ( $I^2 = 72.0\%$ ). No possible explanation of the heterogeneity was found by inspection of baseline characteristics of these studies (Table 1). Moreover, omitting studies one by one did neither result in substantial changes of the pooled HR nor in a reduction of the heterogeneity, indicated by the  $I^2$  (data not shown).

Sub-group NMA showed that the efficacy of regimens with capecitabine, S-1 and 5-FU in Asian and Western studies was in line with the overall results of the entire study population: no differences in Asian and Western patients were observed in terms of OS and PFS (Table 2).

**Toxicity.** In Fig. 4A,B and C, the occurrence of grade 1-2 and 3-4 AEs is shown for respectively capecitabine-based versus 5-FU-based, S-1 based versus 5-FU-based and S-1 based versus capecitabine-based regimens. Per comparison, we indicated if a specific AE occurred in both Asian and Western studies, Western studies only or Asian studies only.

For 5-FU-based compared to capecitabine-based regimens, also thrombo-embolic AE's were extracted from a separate published article of the REAL-2 study<sup>26</sup>. Compared to 5-FU-based regimens, capecitabine-based regimens were associated with a higher rate of grade 1-2 and grade 3-4 hand-foot syndrome in both Asian and Western patients (Fig. 4A). In Western patients only, capecitabine-based regimens were associated with a higher rate of grade 2-3 deep venous thrombosis (DVT), but with a lower rate of grade 1-2 stomatitis and mucositis compared to 5-FU regimens. None of the adverse events showed a statistical significant difference between capecitabine-based and 5-FU-based regimens in Asian patients only.

S-1 based regimens were associated with a lower incidence of several grade 1-2 AEs and grade 3-4 dehydration compared to 5-FU-based regimens in both Asian and Western patients (Fig. 4B). In Western patients only, S-1 based regimens were associated with more grade 1-2 hand-foot syndrome, but with less catheter-related complications, and grade 3-4 mucositis, stomatitis, febrile neutropenia and toxicity-related-deaths compared to 5-FU-based regimens, as we described previously<sup>6</sup>. In Asian patients only, S-1 based regimens were associated with more grade 1-2 abdominal pain and grade 3-4 fatigue, but with less grade 1-2 nausea and weight loss compared to 5-FU-based regimens.

Finally, as Western studies have not been conducted to assess S-1 versus capecitabine therapy regimens, only three Asian studies reported toxicity for this comparison. A lower rate of grade 3-4 neutropenia and grade 1-2 hand-foot syndrome was found for S-1 based regimens compared to capecitabine-based regimens in Asian patients only (Fig. 4C).

**Publication bias.** No evidence for publication bias was found in the Funnel plots for all comparisons and outcomes (Supplementary Figure 2).

## Discussion


This network meta-analysis of all available RCTs that have been conducted in the past decade provides a precise and cross-validated effect estimate of the fluoropyrimidines 5-FU, capecitabine and S-1 in the first-line treatment of advanced esophagogastric cancer. We showed that there is no difference in overall survival and progression-free-survival between 5-FU, capecitabine and S-1-based chemotherapy. In clinical practice, oral fluoropyrimidines capecitabine and S-1 are generally more convenient for patients compared to infusional 5-FU. On the other hand, for patients with dysphagia, which is common in gastro-oesophageal cancer, infusional 5-FU may be more suitable.

Study	N	Arms	Ethnicity	Male	Age	Stage IV	WHO $\geq 2$	GEJ	Stomach
			Asian or Western	N (%)	median (range)	N (%)	N (%)	N (%)	N (%)
<b>Capecitabine vs 5-FU</b>									
Cunningham 2008 <sup>11*</sup>	250	Epi + Cis + Cap	Western	201 (81)	64 (25–82)	192 (77)	31 (12)	68 (28)	102 (42)
	244	Epi + Ox + Cap		202 (83)	62 (25–80)	185 (76)	24 (10)	53 (22)	104 (44)
	263	Epi + Cis + 5-FU		214 (81)	65 (22–83)	209 (80)	31 (12)	72 (29)	90 (36)
	245	Epi + Ox + 5-FU		199 (81)	61 (33–78)	189 (77)	21 (9)	55 (23)	87 (37)
Kang 2009 <sup>12</sup>	160	Cis + Cap	Asian	103 (64)	56 (26–74)	160 (100)	†16 (10)	0 (0)	160 (100)
	156	Cis + 5-FU		108 (69)	56 (22–73)	156 (100)	†17 (11)	0 (0)	156 (100)
Ocvick 2012 <sup>17</sup>	45	Epi + Cis + 5-FU	Western	34 (76)	55 (20–72)	37 (82)	3 (6)	0 (0)	45 (100)
	40	Epi + Cis + Cap		32 (80)	56 (40–77)	35 (88)	2 (5)	0 (0)	40 (100)
Van Cutsem 2015 <sup>14</sup>	89	DTX + Ox + 5-FU/Lv	Western	61 (69)	††58	89 (100)	2 (2)	35 (39)	75 (84)
	86	DTX + Ox + Cap		64 (74)	††59	86 (100)	3 (3)	28 (33)	75 (87)
<b>S-1 vs 5-FU</b>									
Ajani 2010 <sup>18</sup>	521	Cis + S-1	Western	382 (73)	59 (18–83)	497 (96)	0 (0)	82 (16)	438 (84)
	508	Cis + 5-FU		347 (68)	60 (20–85)	488 (96)	0 (0)	88 (17)	417 (82)
Ajani 2015 <sup>19</sup>	239	Cis + S-1	Western	124 (52)	56 (25–86)	239 (100)	0 (0)	16 (7)	223 (93)
	122	Cis + 5-FU		60 (49)	56 (27–83)	122 (100)	0 (0)	5 (4)	117 (96)
Boku 2009 <sup>20</sup>	234	S-1	Asian	175 (75)	64 (58–69)	234 (100)	3 (1)	0 (0)	234 (100)
	234	5-FU		176 (75)	64 (57–69)	234 (100)	3 (1)	0 (0)	234 (100)
Huang 2013 <sup>21</sup>	119	PTX + S-1	Asian	89 (75)	56 (18–74)	112 (94)	Median KPS 80	NA	NA
	110	PTX + 5-FU/Lv		76 (69)	54 (19–72)	102 (93)	Median KPS 80	NA	NA
Jin 2008 <sup>22</sup>	74	Cis + S-1	Asian	55 (74)	57 (24–80)	74 (100)	8 (11)	0 (0)	74 (100)
	73	Cis + 5-FU		61 (84)	58 (33–77)	73 (100)	10 (14)	0 (0)	73 (100)
Li 2015 <sup>23</sup>	120	Cis + S-1	Asian	84 (70)	53 (25–76)	120 (100)	7 (6)	22 (18)	70 (58)
	118	Cis + 5-FU		85 (73)	55 (21–76)	118 (100)	4 (3)	10 (8)	73(63)
Nishikawa 2012 <sup>24</sup>	77	PTX + S-1	Asian	53 (69)	67 (40–82)	77 (100)	0 (0)	0 (0)	77 (100)
	80	PTX + 5-FU		60 (75)	67 (47–90)	80 (100)	0 (0)	0 (0)	80 (100)
Sawaki 2009 <sup>25</sup>	88	S-1	Asian	66 (75)	63 (32–77)	68 (77)	3 (3)	0 (0)	88 (100)
	89	5-FU/Lv		71 (80)	65 (44–77)	65 (73)	4 (4)	0 (0)	89 (100)
<b>S-1 vs Capecitabine</b>									
Kim 2012 <sup>8</sup>	65	Ox + S-1	Asian	44 (68)	60 (28–77)	47 (72)	0 (0)	0 (0)	65 (100)
	64	Ox + Cap		45 (70)	61 (20–75)	46 (72)	0 (0)	0 (0)	64 (100)
Kobayashi 2015 <sup>9</sup>	54	Cis + S-1	Asian	30 (55)	65 (44–74)	54 (100)	1 (2)	0 (0)	54 (100)
	55	Cis + Cap		45 (81)	65 (25–74)	55 (100)	2 (4)	0 (0)	55 (100)
Lee 2008 <sup>10</sup>	45	S-1	Asian	37 (82)	71 (65–82)	45 (100)	2 (4)	NA	NA
	46	Cap		30 (65)	71 (66–78)	46 (100)	4 (9)	NA	NA

**Table 1.** Baseline characteristics. Abbreviations: 5-FU: 5-fluorouracil, Cap: capecitabine, Cis: cisplatin, DTX: docetaxel, Epi: Epirubicin, GEJ: gastro-esophageal junction, KPS: Karnofsky Performance Status, Lv: leucovorin, Ox: oxaliplatin, PTX: paclitaxel. Notes: \*This study also included patients with esophageal carcinoma. †KPS  $\leq 80$  was given instead of WHO. ††Mean age was given instead of median age, performance status.

In addition to what was already known from previously conducted meta-analyses and pooled analyses<sup>2,13</sup>, this NMA shows important new insights that are directly relevant for clinical practice. First, as there are only three small phase II RCTs in Asian populations that compared S-1 based and capecitabine-based regimens<sup>8–10</sup>, with the results derived from our indirect comparison we now can be more confident that S-1 based regimens have equal efficacy compared to capecitabine-based regimens in both Asian and Western patients. Combined with the other evidence for efficacy of S-1 based and 5-FU based regimens in Asian and Western patients presented in this NMA, we can conclude that the three fluoropyrimidines are equally effective in Western and Asian patients. This finding is important for both clinical practice and future RCTs, as practically all globally used first-line chemotherapy and targeted therapy regimens have fluoropyrimidine backbones<sup>5</sup>.

Second, we found that the fluoropyrimidines have a different toxicity profile in Asian patients, Western patients and in the population as a whole. Capecitabine-based regimens were associated with a higher incidence of clinically relevant adverse events hand-foot syndrome in Asian and Western patients and with DVT in Western patients compared to regimens including conventional 5-FU. However, there is a substantial risk of catheter-related (thrombo-embolic) complications with 5-FU, which is administered by continuous venous infusion. Also, 5-FU based regimens are associated with a clinically relevant increased incidence of stomatitis and



**Figure 3.** Results of the network meta-analysis for capecitabine, 5-FU and S-1 based regimens. **(A)** Forest plot of network meta-analysis for overall survival. **(B)** Forest plot for progression free survival. The lower pooled effect-size represents the combined hazard ratio and 95% Credible Intervals (95%CrI) derived from network-meta analysis. Abbreviations: 5-FU: 5-fluorouracil.

mucositis compared to regimens including oral fluoropyrimidines. On the other hand, S-1 based regimens were associated with less clinically relevant adverse events compared to regimens including conventional 5-FU, such as less febrile neutropenia and toxicity related deaths in Western patients and less grade 1-2 hand-foot syndrome compared to regimens including capecitabine in Asian patients. Although S-1 regimens also showed a lower rate of grade 3-4 hand-foot syndrome compared to capecitabine regimens (0% versus 3%), this difference did not reach statistical significance. From clinical perspective, occurrence of hand-foot syndrome is a very relevant

	Overall survival		Progression free survival	
	Asian	Western	Asian	Western
Capecitabine vs 5-FU	0.84 (0.59–1.18)	0.92 (0.64–1.36)	0.82 (0.49–1.36)	1.06 (0.63–2.03)
S-1 vs 5-FU	0.90 (0.71–1.13)	0.94 (0.62–1.47)	0.84 (0.60–1.20)	0.94 (0.52–1.66)
S-1 vs capecitabine	1.08 (0.78–1.52)	1.02 (0.58–1.81)	1.03 (0.61–1.74)	1.00 (0.44–2.28)

**Table 2.** Network meta-analysis stratified by Asian and Western studies in overall survival and progression free survival. Relative effects in combined hazard ratio and 95% Credible Intervals (95% CrI) derived from network-meta analysis for capecitabine, 5-FU and S-1 based cytotoxic regimens stratified by Asian studies and Western studies for overall survival and progression free survival. No significant differences were found among Asian and Western patients in efficacy between all fluoropyrimidines. Abbreviations: 5-FU: 5-fluorouracil.

parameter to monitor the well-being and quality of life of the patients receiving oral capecitabine. In a recently published phase III RCT in metastatic colorectal cancer, the occurrence of hand-foot syndrome, which was the primary endpoint, was significantly reduced in S-1 treated patients compared to capecitabine treated patients, without compromising efficacy<sup>27</sup>. These results are in line with our current findings for advanced esophagogastric cancer. The decision which fluoropyrimidine to prescribe for the individual patient should therefore be based on differences in toxicity profile.

We should also acknowledge some limitations of our work. This NMA was based on extracted summary data from published articles rather than on individual patient data. Second, many articles do not report adverse events that occurred less than a predefined percentage per study arm, which was most often a percentage of 5%. Although we provided a large overview of the toxicity profiles associated with these fluoropyrimidines in both Asian and Western patients, some adverse events may not have been included in the analyses. Third, for the analyses we assumed that the efficacy and toxicity of compounds that were identical in both arms of studies (i.e. cisplatin in the comparison S-1 plus cisplatin versus 5-FU plus cisplatin), was equal in both arms, so that the differences in efficacy and toxicity could be attributed to the fluoropyrimidines only (in this example: S-1 versus 5-FU). Due to slight differences in dosage (e.g. the dose of cisplatin in the FLAGS study<sup>18</sup>), effects cannot fully be attributed to differences in the fluoropyrimidines, but may be due to differences in the companion drug.

In conclusion, we found no difference in overall survival and progression-free-survival between 5-FU, capecitabine and S-1-based first-line chemotherapy for advanced esophagogastric cancer in both Asian and Western patients. The three fluoropyrimidines showed a different toxicity profile, and some relevant adverse events were observed with a lower frequency for S-1 based compared to 5-FU-based regimens (i.e. toxicity-related-death and febrile neutropenia) and capecitabine-based regimens (i.e. hand-foot syndrome).

## Material and Methods


**Protocol.** The protocol was registered in PROSPERO with registration number: CRD42014015177.

**Literature search.** We searched databases Medline, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) and meeting abstracts from the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) for randomized controlled trials up to January 2016. Medical subject headings (MeSH) and text words for esophagogastric cancer and for each treatment option, as described previously (Supplementary Table 1)<sup>28</sup>. The titles and abstracts were screened by NHM and MA. EtV and NHM screened the full articles. Disagreements were discussed with HvL until consensus was reached.

**Study selection.** We included prospective phase II or III randomized controlled trials comparing first-line 5-FU, capecitabine or S-1 based chemotherapy regimens with equal backbones for previously untreated patients with pathologically proven metastatic, unresectable or recurrent adenocarcinoma of the stomach, esophagus, or GEJ.

**Data extraction and quality assessment.** The primary outcome of our analyses was overall survival (OS). In addition, progression-free-survival (PFS), grade 1-2 (mild), and grade 3-4 (severe) adverse events (AE) were secondary outcomes. The Cochrane Risk of bias tool (version 5.1.0) was used to assess the quality of the included studies. Items were scored as low, high or unknown risk of bias.

**Statistical Analysis.** Hazard ratios (HR) with 95% confidence intervals (95%CI) were extracted for time-to-event outcomes OS and PFS. Random effects pair-wise meta-analysis was conducted for direct comparisons simultaneously in R and Review Manager 5.3. For the NMA, studies were analysed in a 3-node network. Random-effects NMA was conducted using JAGS and the GeMTC package in R<sup>29,30</sup> (<https://drugis.org/software/r-packages/gemtc>). For the between studies heterogeneity and the relative treatment effects, vague priors were set. Four independent Markov chains were generated and ran for 5,000 adaptations and 20,000 inference iterations per chain to calculate the posterior distribution. Convergence of the Markov chains was assessed using Brooks-Gelman-Rubin diagnostic and the length of running time was extended if needed. HRs and 95% credible intervals (95%CrI) were calculated as effect-size to represent the combined direct and indirect relative treatment effects. In addition, the incidence of grade 1-2 and 3-4 adverse were compared using dichotomous pair-wise meta-analysis with Risk Ratios (RRs). In case of statistically significant heterogeneity, as determined by the Q-test, heterogeneity was explored by sensitivity analyses.



**Figure 4.** Toxicity of capecitabine, 5-FU and S-1 based regimens. **(A)** Toxicity of capecitabine-based compared to 5-FU-based regimens. **(B)** Toxicity of S-1 based compared to 5-FU-based regimens. **(C)** Toxicity of S-1 based compared to capecitabine-based regimens. The table shows the number of patients receiving that experienced grade 1-2 and grade 3-4 adverse events and the associated sample sizes for each treatment. The bar chart shows the percentage of both Western and Asian patients (overall) that experienced grade 1-2 and grade 3-4 adverse events and corresponds to the ‘overall’ column in the table. The number of adverse events that occurred in the Western subgroup or the Asian subgroup specifically are shown in the ‘Western’ and ‘Asian’ columns of the table. Bold indicates a statistically significant difference ( $P < 0.05$ ) in the occurrence of a given adverse event between two regimens determined by pair-wise meta-analysis. The number of adverse events for Western and Asian patients in Fig. 4B and C are a graphically representation of the data as published elsewhere<sup>6</sup>. However, in the current figures, additional adverse events were included, as well as the pooled number of adverse events of Western and Asian patients. Abbreviations: 5-FU: 5-fluorouracil, Cap: capecitabine, Trt: treatment.

To evaluate differences in efficacy between fluoropyrimidines in Asian and Western patients, sub-group NMs were conducted for studies in Asian and Western populations. Publication bias was assessed by funnel plots. All meta-analyses were performed using random-effects models and tested two-sided with  $\alpha = 0.05$ .

**References**

1. Torre L. A. *et al.* Global cancer statistics. *CA Cancer J Clin* 2015, **65**, 87–108 (2012).
2. Wagner A. D. *et al.* Chemotherapy for advanced gastric cancer. *Cochrane Database Sys Rev*: Cd004064 (2010).
3. Waddell, T. *et al.* Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Eur J Surg Oncol* **40**, 584–91 (2014).
4. Ajani, J. A. *et al.* Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. *J. Natl Compr Canc Netw* **11**, 531–46 (2013).
5. Lordick, F., Lorenzen, S., Yamada, Y. & Ilson, D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? *Gastric Cancer* **17**, 213–25 (2014).
6. Ter Veer, E. *et al.* The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. *Gastric Cancer* **19**, 696–712 (2016).
7. Ma, B. B., Hui, E. P. & Mok, T. S. Population-based differences in treatment outcome following anticancer drug therapies. *Lancet Oncol* **11**, 75–84 (2010).
8. Kim, G. M. *et al.* A randomized phase II trial of S-1-oxaliplatin versus capecitabine oxaliplatin in advanced gastric cancer. *Eur J Cancer* **48**, 518–26 (2012).
9. Kobayashi M. *et al.* A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XPaTS II). *Gastrointestinal Cancers Symposium. J Clin Oncol*, suppl 3, abstr 105 (2015).

10. Lee, J. L. *et al.* A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. *Br J Cancer* **99**, 584–90 (2008).
11. Cunningham, D. *et al.* Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* **358**, 36–46 (2008).
12. Kang, Y. K. *et al.* Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* **20**, 666–73 (2009).
13. Okines, A. F., Norman, A. R., McCloud, P., Kang, Y. K. & Cunningham, D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. *Ann Oncol* **20**, 1529–34 (2009).
14. Cutsem, E. *et al.* Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study. *Ann. Oncol.* **26**, 149–56 (2015).
15. Cipriani, A., Barbui, C., Rizzo, C. & Salanti, G. What is a multiple treatments meta-analysis? *Epidemiol Psychiatr Sci* **21**, 151–3 (2012).
16. Lu, G. & Ades, A. E. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* **23**, 3105–24 (2004).
17. Ocvirk, J., Rebersek, M., Skof, E., Hlebanja, Z. & Boc, M. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5 fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer. *Am J Clin Oncol* **35**, 237–41 (2012).
18. Ajani, J. A. *et al.* DIGEST Study Group. Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial). *J Clin Oncol*, **33**, 15 suppl 4015 (2015).
19. Ajani, J. A. *et al.* Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. *J Clin Oncol* **28**, 1547–53 (2010).
20. Boku, N. *et al.* Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. *Lancet Oncol* **10**, 1063–9 (2009).
21. Huang, D. *et al.* A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. *Eur J. Cancer* **49**, 2995–3002 (2013).
22. Jin M. *et al.* Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. *J Clin Oncol*, **26** (2008).
23. Li, Y. H. *et al.* S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. *Oncotarget* **6**, 35107–15 (2015).
24. Nishikawa, K. *et al.* A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. *Gastric Cancer* **15**, 363–9 (2012).
25. Sawaki, A. *et al.* 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial (ISO-5FU10 Study Group trial). *EJC Supplements* **7**(2), 364 (2009).
26. Starling, N. *et al.* Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. *J Clin Oncol* **27**, 3786–93 (2009).
27. Kwakman J. J. *et al.* Randomised phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. *Ann Oncol.* doi:10.1093/annonc/mdx122 (2017).
28. Ter Veer, E. *et al.* The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. *J Natl Cancer Inst*, **108** (2016)
29. Dias, S., Sutton, A. J., Ades, A. E. & Welton, N. J. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making* **33**, 607–17 (2013).
30. van Valkenhoef, G. *et al.* Automating network meta-analysis. *Res Synth Methods* **3**, 285–99 (2012).

## Acknowledgements

This work was supported by an unrestricted grant from Nordic Pharma.

## Author Contributions

Literature search: E.t.V., N.H.M., M.A. Quality assessment: E.t.V., N.H.M., H.v.L. Data extraction: E.t.V., L.N., N.H.M. Statistical analysis: G.v.V., L.N., E.t.V. Manuscript writing: E.t.V., L.N., N.H.M., H.v.L., M.v.O., G.v.V. Overview of the study: M.v.O., H.v.L. All authors gave final approval for submission of the manuscript.

## Additional Information

**Supplementary information** accompanies this paper at doi:10.1038/s41598-017-07750-3

**Competing Interests:** Dr. Martijn G. H. van Oijen has received unrestricted research grants from Bayer, Lilly, Merck Serono, and Roche. Prof. Dr. Hanneke W. M. van Laarhoven has served as a consultant for Celgene, Lilly, and Nordic, and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, and Roche. Dr. Gert H. M. van Valkenhoef has served as a consultant for Johnson & Johnson. All other authors have no disclosures to report.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017